Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18688805 | 0.84 | MAPT (0.54) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL18689411 | 0.83 | THRB (0.49) | ALDH1A1MEN1KMT2ATHRBMAPT | |
| SCHEMBL18689399 | 0.83 | MAPT (0.50) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL18688796 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATHRBMAPT | |
| SCHEMBL18689403 | 0.81 | MAPT (0.51) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL18688793 | 0.81 | RXFP1 (0.48) | ALDH1A1MEN1KMT2ATHRBMAPT | |
| SCHEMBL18689398 | 0.81 | POLB (0.50) | ALDH1A1MEN1KMT2ATHRBMAPT | |
| SCHEMBL18688795 | 0.80 | LMNA (0.45) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL18689405 | 0.80 | ESR2 (0.45) | ALDH1A1THRBMAPTGAAPOLB | |
| SCHEMBL11887719 | 0.79 | THRB (0.46) | ALDH1A1MEN1KMT2ATHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3353156-B1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| WO-2017053706-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | TEAD1, TEAD2, TEAD3 | ALDH1A1 4216/4885MEN1 3771/4885KMT2A 641/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885MEN1 3307/4885KMT2A 2717/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885MEN1 3307/4885KMT2A 2717/4885 |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | TEAD1, TEAD2, TEAD3 | ALDH1A1 4216/4885MEN1 3771/4885KMT2A 641/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885MEN1 3307/4885KMT2A 2717/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885MEN1 3307/4885KMT2A 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.